Anemia Drugs: A Global Strategic Business Report
San Jose, CA (PRWEB) April 15, 2010
Anemia is a condition characterized by reduced levels of hemoglobin or red blood corpuscles (RBCs) in the blood. It could either be simply due to iron deficiency, known as iron deficiency anemia, or could result from an underlying chronic disease or due to treatment of an underlying chronic disease, known as chronic anemia. There are millions of anemia sufferers worldwide, and about three-quarters of all anemia patients, are in need of treatment. This indicates that millions of anemia patients remain untreated, and the currently available treatments are not only expensive, but also have an unfavorable side-effects profile.
The United States dominates the world anemia drugs market as stated by the new market research report on anemia drugs market. The largest contributors to sales of anemia drugs include dialysis patients, followed by oncology and pre-dialysis patients. Despite the growing incidence of anemia, as more baby boomers continue to age, the sales of recombinant erythropoietin (rEPO) and epoetin alfa (EPO) have been declining in recent years. The sales started declining when studies conducted in the previous few years showed high doses of ESAs to lead to heart complications and even death in a few instances, resulting in the FDA ordering strong warnings to be added to product labels, causing the sales to decline significantly.
Europe is another leading market for anemia drugs, which too is declining in terms of value sales, but not at rates as high as that of the US. Indeed, unlike the US market, the European decline is led by the foray of biogenerics into the anemia domain. Europe has been the first to approve the use of biosimilars in the world, and the first to frame regulatory procedure for biosimilars approval in the region. With epoetin alfa (EPO) Epogen going off patent in Europe in 2004, the opportunity available to biogeneric companies in this area had been large and lucrative.
Key players profiled in the report include Acceleron Pharma, Inc.; Akebia Therapeutics, Inc.; Amgen, Inc.; Bristol-Myers Squibb Company; Centocor Ortho Biotech Products, LP; F. Hoffmann-La Roche Ltd; Chugai Pharmaceutical Co. Ltd.; Fibrogen, Inc.; GlaxoSmithKline PLC; Hospira, Inc.; Novartis International AG; Pfizer, Inc.; ProMetic Life Sciences, Inc.; and Takeda Pharmaceutical Company Limited.
The report titled "Anemia Drugs: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of market, market inhibitors, pipeline status, clinical trials, product introductions/ approvals, and recent industry activity. The study analyzes market data and analytics in terms of value sales for regions including The United States, Europe and Rest of World. The study provides analytics in terms of value sales for the global and the US market by the following segments - Short Acting ESAs and Long Acting ESAs.
For more details about this market research report, please visit - http://www.strategyr.com/Anemia_Drugs_Market_Report.asp
About Global Industry Analysts, Inc.:
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site http://www.StrategyR.com/